FDA resumes eIND approval for use of CytoDyn leronlimab in COVID-19

 

• CytoDyn (OTCQB:CYDY) announces that a treating physician has received authorization from the FDA to administer leronlimab for a COVID-19 patient under emergency IND (eIND).
• In recent months, leronlimab has received more than 60 eIND authorizations from the FDA.
• FDA’s decision will enable the company to respond to ongoing requests for leronlimab until Phase 3 trial data is unblinded.
• CytoDyn has completed enrollment in its Phase 3 trial.
• Leronlimab has become a debate topic over its ability to help COVID-19 patients, or even become a "cure" for this terrible pandemic.
• https://seekingalpha.com/news/3646517-fda-resumes-eind-approval-for-use-of-leronlimab-in-covidminus-19